TJ342B - Derivatives of 6-aryl pyrido Ä2,3-dÜ pyrimidines and naphthyridines pharmaceutical composition possess inhibiting effect of cellular proliferation pr ovoking protein tyrosine kinase and method of inhibiting cellular proliferation - Google Patents

Derivatives of 6-aryl pyrido Ä2,3-dÜ pyrimidines and naphthyridines pharmaceutical composition possess inhibiting effect of cellular proliferation pr ovoking protein tyrosine kinase and method of inhibiting cellular proliferation

Info

Publication number
TJ342B
TJ342B TJ97000469A TJ97000469A TJ342B TJ 342 B TJ342 B TJ 342B TJ 97000469 A TJ97000469 A TJ 97000469A TJ 97000469 A TJ97000469 A TJ 97000469A TJ 342 B TJ342 B TJ 342B
Authority
TJ
Tajikistan
Prior art keywords
cellular proliferation
inhibiting
naphthyridines
tyrosine kinase
protein tyrosine
Prior art date
Application number
TJ97000469A
Other languages
English (en)
Inventor
Clifton John Blankley
Annette Marian Doherty
James Marino Hamby
Robert Lee Panek
Mel Conrad Shroeder
Howard Daniel Hollis Owalter
Cleo Connolly
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/539,410 external-priority patent/US5733913A/en
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of TJ342B publication Critical patent/TJ342B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
TJ97000469A 1994-11-14 1995-11-13 Derivatives of 6-aryl pyrido Ä2,3-dÜ pyrimidines and naphthyridines pharmaceutical composition possess inhibiting effect of cellular proliferation pr ovoking protein tyrosine kinase and method of inhibiting cellular proliferation TJ342B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33905194A 1994-11-14 1994-11-14
US08/539,410 US5733913A (en) 1994-11-14 1995-11-06 6-Aryl pyrido 2,3-d! pyrimidines and naphthyridines for inhibiting protein tyrosine kinase mediated cellular proliferation

Publications (1)

Publication Number Publication Date
TJ342B true TJ342B (en) 2002-10-06

Family

ID=26991470

Family Applications (1)

Application Number Title Priority Date Filing Date
TJ97000469A TJ342B (en) 1994-11-14 1995-11-13 Derivatives of 6-aryl pyrido Ä2,3-dÜ pyrimidines and naphthyridines pharmaceutical composition possess inhibiting effect of cellular proliferation pr ovoking protein tyrosine kinase and method of inhibiting cellular proliferation

Country Status (25)

Country Link
US (1) US5952342A (cs)
EP (1) EP0790997B1 (cs)
CN (1) CN1085666C (cs)
AT (1) ATE190978T1 (cs)
AU (1) AU711426B2 (cs)
BG (1) BG63162B1 (cs)
CZ (1) CZ286160B6 (cs)
DE (1) DE69515898T2 (cs)
DK (1) DK0790997T3 (cs)
ES (1) ES2146782T3 (cs)
FI (1) FI971953L (cs)
GE (1) GEP20012444B (cs)
GR (1) GR3033439T3 (cs)
HU (1) HUT76853A (cs)
IL (1) IL115970A (cs)
MD (1) MD1861G2 (cs)
MX (1) MX9702245A (cs)
NO (1) NO308250B1 (cs)
NZ (1) NZ296456A (cs)
PL (1) PL181893B1 (cs)
PT (1) PT790997E (cs)
RU (1) RU2191188C2 (cs)
SK (1) SK281724B6 (cs)
TJ (1) TJ342B (cs)
WO (1) WO1996015128A2 (cs)

Families Citing this family (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5620981A (en) * 1995-05-03 1997-04-15 Warner-Lambert Company Pyrido [2,3-D]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation
IL117923A (en) * 1995-05-03 2000-06-01 Warner Lambert Co Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds
HRP970371A2 (en) 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
EP0912559B1 (en) 1996-07-13 2002-11-06 Glaxo Group Limited Fused heterocyclic compounds as protein tyrosine kinase inhibitors
US6498163B1 (en) 1997-02-05 2002-12-24 Warner-Lambert Company Pyrido[2,3-D]pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation
DE69839338T2 (de) * 1997-02-05 2008-07-10 Warner-Lambert Company Llc Pyrido (2,3-d) pyrimidine und 4-amino-pyrimidine als inhibitoren der zellulären proliferation
EP1806348A3 (en) * 1997-02-05 2008-01-02 Warner-Lambert Company LLC Pyrido [2, 3 -d] pyrimidines and 4-amino-primidines as inhibitors of cellular proliferation
EP1003745B1 (en) * 1997-08-20 2004-12-29 Warner-Lambert Company Llc Naphthyridinones for inhibiting protein tyrosine kinase and cell cycle kinase mediated cellular proliferation
EP1801112A1 (en) * 1998-05-26 2007-06-27 Warner-Lambert Company LLC Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation
TR200003429T2 (tr) 1998-05-26 2001-07-23 Warner-Lambert Company Hücresel çoğalma inhibitörleri olarak bisiklik pirimidinler ve bisiklik 3,4-dihidropirimidinler.
GB9822450D0 (en) * 1998-10-14 1998-12-09 Smithkline Beecham Plc Medicaments
GB9914486D0 (en) 1999-06-21 1999-08-18 Smithkline Beecham Plc Medicaments
GB9917406D0 (en) 1999-07-23 1999-09-22 Smithkline Beecham Plc Compounds
GB9917408D0 (en) 1999-07-23 1999-09-22 Smithkline Beecham Plc Compounds
US7053070B2 (en) * 2000-01-25 2006-05-30 Warner-Lambert Company Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors
AR030044A1 (es) * 2000-01-25 2003-08-13 Warner Lambert Co Pirido (2,3-d ) pirimidin-2,7-diaminas inhibidores de quinasas
JP2004504397A (ja) 2000-07-26 2004-02-12 スミスクライン　ビーチャム　パブリック　リミテッド　カンパニー 抗菌活性を有するアミノピペリジンキノリン類およびそれらのアザイソステリックアナログ類
US6518276B2 (en) * 2000-08-31 2003-02-11 Syntex (U.S.A.) Llc 7-oxo-pyridopyrimidines (II)
EP1315726A1 (en) * 2000-08-31 2003-06-04 F. Hoffmann-La Roche Ag 7- oxo pyridopyrimidines as inhibitors of cellular proliferation
US6506749B2 (en) 2000-08-31 2003-01-14 Syntex (U.S.A.) Llc 7-oxo-pyridopyrimidines (I)
US20020119148A1 (en) * 2000-09-01 2002-08-29 Gerritsen Mary E. ErbB4 antagonists
ATE320255T1 (de) * 2001-01-19 2006-04-15 Smithkline Beecham Corp Tie2 rezeptor-kinase-inhibitoren zur behandlung von angiogenen erkrankungen
GB0101577D0 (en) 2001-01-22 2001-03-07 Smithkline Beecham Plc Compounds
MXPA03007166A (es) * 2001-02-12 2003-11-18 Hoffmann La Roche Pirido-pirimidinas 6-sustituidas.
WO2002090360A1 (en) * 2001-05-10 2002-11-14 Smithkline Beecham Corporation Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
GB0112836D0 (en) 2001-05-25 2001-07-18 Smithkline Beecham Plc Medicaments
GB0112834D0 (en) 2001-05-25 2001-07-18 Smithkline Beecham Plc Medicaments
US20030105115A1 (en) * 2001-06-21 2003-06-05 Metcalf Chester A. Novel pyridopyrimidines and uses thereof
IL162721A0 (en) 2002-01-22 2005-11-20 Warner Lambert Co 2-(Pyridin-2-ylamino)-pyridoÄ2,3-dÜpyrimidin-7-ones
AR038240A1 (es) 2002-01-29 2005-01-05 Glaxo Group Ltd Compuesto de piperidina, uso del mismo para la fabricacion de un medicamento, composicion farmaceutica que lo comprende y procedimiento para su preparacion
WO2003064431A2 (en) 2002-01-29 2003-08-07 Glaxo Group Limited Aminopiperidine compounds, process for their preparation, and pharmaceutical compositions containing them
AU2003211594A1 (en) * 2002-03-05 2003-09-16 Eisai Co., Ltd. Antitumor agent comprising combination of sulfonamide-containing heterocyclic compound with angiogenesis inhibitor
PA8577501A1 (es) 2002-07-25 2004-02-07 Warner Lambert Co Inhibidores de quinasas
WO2004014907A1 (en) 2002-08-06 2004-02-19 F. Hoffmann-La Roche Ag 6-alkoxy-pyrido-pyrimidines as p-38 map kinase inhibitors
US7098332B2 (en) * 2002-12-20 2006-08-29 Hoffmann-La Roche Inc. 5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones
TW200502236A (en) * 2003-03-28 2005-01-16 Hoffmann La Roche Novel pyrido[2,3-d]pyrimidin-7-carboxylic acid derivatives, their manufacture and use as pharmaceutical agents
RU2263146C2 (ru) * 2003-07-10 2005-10-27 Михаил Викторович Разуменко Способ получения бактериофагов, специфично связывающихся с клетками-мишенями и предназначенных для терапевтических целей
DE602004017474D1 (de) * 2003-07-11 2008-12-11 Warner Lambert Co Isethionat salz eines selektiven cdk4 inhibitors
WO2005047284A1 (en) 2003-11-13 2005-05-26 F. Hoffmann-La Roche Ag Hydroxyalkyl substituted pyrido-7-pyrimidin-7-ones
ATE481134T1 (de) 2004-01-21 2010-10-15 Univ Emory Zusammensetzungen und verwendung von tyrosinkinase-hemmern zur behandlung von pathogenen infektionen
BRPI0508706A (pt) 2004-03-15 2007-08-07 Hoffmann La Roche derivados de dicloro-fenil-pirido[2,3-d]pirimidina inusitados, sua fabricação e uso como agentes farmacêuticos
FR2873118B1 (fr) * 2004-07-15 2007-11-23 Sanofi Synthelabo Derives de pyrido-pyrimidine, leur application en therapeutique
CA2579406A1 (en) * 2004-09-21 2006-03-30 F.Hoffmann-La Roche Ag 6-(2-alkyl-phenyl) - pyrido[2,3-d] pyrimidines useful as protein kinase inhibitors
US20070054916A1 (en) † 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
WO2006045010A2 (en) * 2004-10-20 2006-04-27 Resverlogix Corp. Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases
EP1833832A1 (en) * 2004-12-31 2007-09-19 GPC Biotech AG Napthyridine compounds as rock inhibitors
FR2887882B1 (fr) * 2005-07-01 2007-09-07 Sanofi Aventis Sa Derives de pyrido[2,3-d] pyrimidine, leur preparation, leur application en therapeutique
JP5368792B2 (ja) 2005-07-29 2013-12-18 レスバーロジックス コーポレイション 複合疾患の予防および処置のための薬学的組成物および挿入可能な医療用デバイスによるその送達
WO2007021795A2 (en) * 2005-08-09 2007-02-22 Irm Llc Compounds and compositions as protein kinase inhibitors
US20070082920A1 (en) * 2005-10-06 2007-04-12 Yongsheng Song NAD+-dependent DNA ligase inhibitors
RU2445315C2 (ru) * 2005-11-22 2012-03-20 Кудос Фармасьютиклз Лимитед ПРОИЗВОДНЫЕ ПИРИДО-, ПИРАЗО- И ПИРИМИДО-ПИРИМИДИНА И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ mTOR
FR2896246B1 (fr) 2006-01-13 2008-08-15 Sanofi Aventis Sa Derives de pyrido-pyrimidone, leur preparation, leur application en therapeutique.
DE602007001952D1 (de) 2006-01-31 2009-09-24 Hoffmann La Roche 7h-pyridoä3,4-düpyrimidin-8-one, ihre herstellung und ihre verwendung als proteinkinaseinhibitoren
SI2074122T1 (sl) 2006-09-15 2011-10-28 Pfizer Prod Inc Pirido (2,3-d)pirimidinonske spojine in njihova uporaba kot zaviralci PI3
WO2008055842A1 (en) * 2006-11-09 2008-05-15 F. Hoffmann-La Roche Ag Substituted 6-phenyl-pyrido [2,3-d] pyrimidin-7-one derivatives as kinase inhibitors and methods for using the same
FR2910813B1 (fr) 2006-12-28 2009-02-06 Sanofi Aventis Sa Nouvelle utilisation therapeutique pour le traitement des leucemies
CN101641339B (zh) 2007-02-01 2013-07-17 雷斯韦洛吉克斯公司 用于预防和治疗心血管疾病的化合物
WO2008104473A2 (en) * 2007-02-28 2008-09-04 F. Hoffmann-La Roche Ag Pyrazolopyriidine derivatives and their use as kinase inhibitors
US20090203709A1 (en) * 2008-02-07 2009-08-13 Abbott Laboratories Pharmaceutical Dosage Form For Oral Administration Of Tyrosine Kinase Inhibitor
US8110578B2 (en) * 2008-10-27 2012-02-07 Signal Pharmaceuticals, Llc Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
AU2010204106B2 (en) 2009-01-08 2014-05-08 Resverlogix Corp. Compounds for the prevention and treatment of cardiovascular disease
WO2010106436A2 (en) 2009-03-18 2010-09-23 Resverlogix Corp. Novel anti-inflammatory agents
KR20190091564A (ko) 2009-04-22 2019-08-06 리스버로직스 코퍼레이션 신규한 소염제
ES2347630B1 (es) * 2009-04-29 2011-09-08 Universitat Ramon Llull Sintesis y usos de 4-cianopentanoatos y 4-cianopentenoatos sustituidos.
GB0922589D0 (en) * 2009-12-23 2010-02-10 Almac Discovery Ltd Pharmaceutical compounds
US8754114B2 (en) 2010-12-22 2014-06-17 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
GB201104267D0 (en) 2011-03-14 2011-04-27 Cancer Rec Tech Ltd Pyrrolopyridineamino derivatives
SI2773354T1 (sl) 2011-11-01 2019-08-30 Resverlogix Corp. Peroralne formulacije s takojšnjim sproščanjem za substituirane kinazolinone
PT3176170T (pt) 2012-06-13 2019-02-05 Incyte Holdings Corp Compostos tricíclicos substituídos como inibidores de fgfr
SI2872491T1 (sl) * 2012-07-11 2021-11-30 Blueprint Medicines Corporation Inhibitorji receptorja fibroblastnega rastnega faktorja
WO2014026125A1 (en) 2012-08-10 2014-02-13 Incyte Corporation Pyrazine derivatives as fgfr inhibitors
GB201216017D0 (en) 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Inhibitor compounds
GB201216018D0 (en) 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Pharmacologically active compounds
US9765039B2 (en) 2012-11-21 2017-09-19 Zenith Epigenetics Ltd. Biaryl derivatives as bromodomain inhibitors
WO2014080290A2 (en) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Cyclic amines as bromodomain inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
WO2014096965A2 (en) 2012-12-21 2014-06-26 Rvx Therapeutics Inc. Novel heterocyclic compounds as bromodomain inhibitors
EP2968337B1 (en) * 2013-03-15 2021-07-21 Celgene CAR LLC Heteroaryl compounds and uses thereof
US9321786B2 (en) 2013-03-15 2016-04-26 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
EP3943087A1 (en) 2013-03-15 2022-01-26 Celgene CAR LLC Heteroaryl compounds and uses thereof
TWI649318B (zh) 2013-04-19 2019-02-01 英塞特控股公司 作為ｆｇｆｒ抑制劑之雙環雜環
HUE059037T2 (hu) 2013-10-25 2022-10-28 Blueprint Medicines Corp Fibroblaszt növekedési faktor receptor gátlók
US9695165B2 (en) 2014-01-15 2017-07-04 Blueprint Medicines Corporation Inhibitors of the fibroblast growth factor receptor
GB201403536D0 (en) 2014-02-28 2014-04-16 Cancer Rec Tech Ltd Inhibitor compounds
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
EP3617205B1 (en) 2015-02-20 2021-08-04 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2016134294A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
EP3268007B1 (en) 2015-03-13 2022-11-09 Resverlogix Corp. Compositions and therapeutic methods for the treatment of complement-associated diseases
KR102548229B1 (ko) * 2015-04-14 2023-06-27 에자이 알앤드디 매니지먼트 가부시키가이샤 결정질 fgfr4 억제제 화합물 및 그의 용도
CN104774183B (zh) * 2015-04-24 2017-10-13 合肥新诺华生物科技有限公司 一种甲酰基瑞舒伐汀钙中间体的制备方法
WO2018023081A1 (en) * 2016-07-29 2018-02-01 Achaogen, Inc. 6-phenylpyrido[2,3-d]pyrimidine compounds as antibacterial agents
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
GB201709840D0 (en) 2017-06-20 2017-08-02 Inst Of Cancer Research: Royal Cancer Hospital Methods and medical uses
BR112020021802A2 (pt) 2018-04-23 2021-02-23 Kyoto University métodos para produzir uma população de células produtoras de insulina ou uma população de células beta pancreáticas e para diminuir o número ou inibir a proliferação de células positivas para ki67, e, população de células progenitoras pancreáticas ou células em um estágio posterior de diferenciação
CA3099116A1 (en) 2018-05-04 2019-11-07 Incyte Corporation Salts of an fgfr inhibitor
MX2020011718A (es) 2018-05-04 2021-02-15 Incyte Corp Formas solidas de un inhibidor de receptores del factor de crecimiento de fibroblastos (fgfr) y procesos para prepararlas.
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
CA3156268A1 (en) * 2019-10-01 2021-04-08 Goldfinch Bio, Inc. CDK5 SUBSTITUTE 1,6-NAPHTYRIDINE INHIBITORS
WO2021067374A1 (en) 2019-10-01 2021-04-08 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
JP7675711B2 (ja) 2019-10-14 2025-05-13 インサイト・コーポレイション Ｆｇｆｒ阻害剤としての二環式複素環
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021113479A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
IL293001A (en) 2019-12-04 2022-07-01 Incyte Corp Derivatives of an fgfr inhibitor
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
TW202304459A (zh) 2021-04-12 2023-02-01 美商英塞特公司 包含ｆｇｆｒ抑制劑及ｎｅｃｔｉｎ－４靶向劑之組合療法
JP2024522189A (ja) 2021-06-09 2024-06-11 インサイト・コーポレイション Ｆｇｆｒ阻害剤としての三環式ヘテロ環

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1171218A (en) * 1967-11-09 1969-11-19 Parke Davis & Co New Heterocyclic Amine Compounds and Methods for their Production
US3639401A (en) * 1969-07-28 1972-02-01 Parke Davis & Co 6-aryl-2 7-bis((trialkylsilyl)amino)pyrido (2 3-d)pyrimidine compounds
US4271164A (en) * 1979-04-16 1981-06-02 Warner-Lambert Company 6-Substituted-arylpyrido[2,3-d]pyrimidin-7-amines and derivatives
US4771054A (en) * 1985-01-23 1988-09-13 Warner-Lambert Company Antibacterial agents
US4771057A (en) * 1986-02-03 1988-09-13 University Of Alberta Reduced pyridyl derivatives with cardiovascular regulating properties
DK172753B1 (da) * 1988-05-25 1999-06-28 Lilly Co Eli N-(5,6,7,8-tetrahydropyrido[2,3--d]pyrimidin-6-yl-alkanoyl)-glutaminsyrederivater, deres anvendelse, farmaceutiske præparat
DE4131029A1 (de) * 1991-09-18 1993-07-29 Basf Ag Substituierte pyrido (2,3-d) pyrimidine als antidots

Also Published As

Publication number Publication date
FI971953A7 (fi) 1997-05-12
PT790997E (pt) 2000-06-30
RU2191188C2 (ru) 2002-10-20
NO308250B1 (no) 2000-08-21
ATE190978T1 (de) 2000-04-15
BG63162B1 (bg) 2001-05-31
IL115970A0 (en) 1996-01-31
SK281724B6 (sk) 2001-07-10
EP0790997A2 (en) 1997-08-27
BG101326A (bg) 1998-04-30
WO1996015128A2 (en) 1996-05-23
PL181893B1 (pl) 2001-10-31
MD970187A (en) 1999-02-28
GEP20012444B (en) 2001-05-25
IL115970A (en) 1999-06-20
HUT76853A (en) 1997-12-29
US5952342A (en) 1999-09-14
CZ286160B6 (cs) 2000-01-12
ES2146782T3 (es) 2000-08-16
SK60997A3 (en) 1998-05-06
GR3033439T3 (en) 2000-09-29
FI971953L (fi) 1997-05-12
CN1169726A (zh) 1998-01-07
FI971953A0 (fi) 1997-05-07
MD1861G2 (ro) 2002-09-30
EP0790997B1 (en) 2000-03-22
AU4107896A (en) 1996-06-06
CN1085666C (zh) 2002-05-29
PL320169A1 (en) 1997-09-15
CZ139097A3 (cs) 1998-02-18
NO972198L (no) 1997-05-13
MD1861F2 (en) 2002-02-28
AU711426B2 (en) 1999-10-14
NO972198D0 (no) 1997-05-13
DE69515898T2 (de) 2000-08-17
MX9702245A (es) 1997-06-28
DE69515898D1 (de) 2000-04-27
DK0790997T3 (da) 2000-08-21
NZ296456A (en) 1999-09-29
WO1996015128A3 (en) 1996-07-11

Similar Documents

Publication Publication Date Title
TJ342B (en) Derivatives of 6-aryl pyrido Ä2,3-dÜ pyrimidines and naphthyridines pharmaceutical composition possess inhibiting effect of cellular proliferation pr ovoking protein tyrosine kinase and method of inhibiting cellular proliferation
IL117923A0 (en) Pyrido [2,3-d] pyrimidine derivatives and pharmaceutical compositions containing them
AP9901435A0 (en) Bicycle heteroaromatic compounds as protein tyrosine kinase inhibitors.
CA2400554A1 (en) Pyrimidine-4-one derivatives as ldl-pla2 inhibitors
MY141144A (en) 1, 5-disubstituted-3,4-dihydro-1h-pyrimido 4,5-dipyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
NO984199D0 (no) Nye N-7-heterocyklylpyrrolo[2,3-D]pyridiner og deres anvendelse
IL139599A0 (en) Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation
PL327735A1 (en) Novel substituted derivatives of imidazole
BRPI0412993A (pt) inibidores da atividade da akt
TR199900049T2 (xx) Protein tirozin kinaz inhibit�rleri olarak bisiklik heteroaromatik bile�ikler.
AU1783201A (en) 3,4-dihydro-(1h)quinazolin-2-one compounds as csbp/p38 kinase inhibitors
AU1781601A (en) 3,4-dihydro-(1h)quinazolin-2-one compounds as csbp/p38 kinase inhibitors
BG105003A (en) Combinations of protein farnesyltransfer and hmg coa reductase inhibitors and their use to treat cancer
CO4920227A1 (es) Histidina-n-bencil glicinamida sustituida con cicloalquilos .
MXPA01002546A (es) Promocion o inibhicion de angiogenesis y cardiovascularizacion.
DE59712297D1 (de) 3-alkylimidazopyridine
ES2036128A1 (es) Procedimiento para la preparacion de 4-(imidazo)1,5-a)piridin-8l)-1,4-dihidropiridinas.